Mangalam Drugs and Organics Limited

Regd: Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
91-22-62616200 / 6300 / 8787 91-22-62619090 • CIN : L24230MH1972PLC116413

MANGALAM
WHO-GMP
Accredited

REF: MDOL/CS-SE/2026- 27/021 **August 12, 2026**

To,

Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: 532637

Listing Department
National Stock Exchange of India Limited
"Exchange Plaza", 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051
Symbol: MANGALAM

Sub: Outcome of the Board Meeting held on Wednesday, August 12, 2026

Ref: Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) read with SEBI Circular CIR / CFD / CMD /4 /2015 dated September 09, 2015

Dear Sir / Madam,

With respect to the captioned subject and mentioned reference, we are pleased to inform that the Board of Directors of the Company, in their meeting held today i.e., Wednesday, August 12, 2026 has *inter-alia* transacted, considered and approved the following business:

1. The Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report of the Company for the quarter ended June 30, 2026 pursuant to Regulation 33 of the SEBI LODR Regulations. (A copy of the said results, notes thereto and Limited Review Report is annexed hereto and marked as Annexure I.)

2. Appointment of M/s L.N. Joshi & Co. Practicing Company Secretaries (CP No.: 4216), as Secretarial Auditors of the Company in line with SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024, for a period of five consecutive years commencing from conclusion of 53rd AGM to 58th AGM of the Company, subject to approval of the members at the ensuing AGM.

3. Approved appointment of M/s S.N. Nanda & Co., Chartered Accountants (FRN:000685N) as the Statutory Auditors of the Company, for a term of five consecutive years, commencing from the conclusion of the 53rd AGM till the conclusion of the 58th AGM, subject to the approval of the shareholders at the ensuing AGM.

MANGALAM DRUGS & ORGANICS LTD. MUMBAI

Mangalam Drugs and Organics Limited

Regd: Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
91-22-62616200 / 6300 / 8787 91-22-62619090 • CIN : L24230MH1972PLC116413

MANGALAM
WHO-GMP
Accredited

Pursuant to Regulation 33(3)(d) of the Listing Regulations, we hereby declare that in respect of the Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, the statutory Auditors have not expressed any modified opinion(s) in their Limited Review Reports.

The Board meeting commenced at 12:30 P.M. and concluded at 3: 40 P.M.

We request you to take the same on your records.

Thanking You,
Yours faithfully,
For **Mangalam Drugs & Organics Limited**

MANGALAM DRUGS & ORGANICS LTD. MUMBAI

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

V. S. SOMANI & CO.
CHARTERED ACCOUNTANTS

UNIT NO.127, 1ST FLOOR, PRABHADEVI UNIQUE INDUSTRIAL PREMISES CO-OP SOCIETY LTD., TWIN TOWER LANE, OFF. VEER SAVARKAR MARG, PRABHADEVI, MUMBAI 400 025.
PHONE NO: 022 66624558
EMAIL ID: vidyadhar@cavssomani.com

Limited Review Report on Unaudited Standalone Financial Results of Mangalam Drugs and Organics Limited for the Quarter ended on 30th June, 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021 as amended.

The Board of Directors,
Mangalam Drugs and Organics Limited,

1. We have reviewed the accompanying statement of Standalone unaudited financial results (the "Statement") of **Mangalam Drugs and Organics Limited** (the "Company") for the quarter ended 30th June 2026 attached herewith, being submitted by the Company, pursuant to the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the requirement of recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (" Listing Regulations") as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

V. S. SOMANI & CO. M. No. FRN: 117 CHARTERED ACCOUNTANTS

4. Conclusion

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V.S. SOMANI & Co.,
Chartered Accountants
Firm Registration No. 117589W

V.S. SOMANI & CO. M. No. 102664 FRN. 117589 CHARTERED ACCOUNTANTS

CA Vidyadhar Somani
Proprietor
MembershipNo.102664
UDIN No. 26102664IXOVN03273

Place: Mumbai
Date: August 12th, 2026

MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413
Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400 001.

Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026

(Rs. In Lakhs)

Sr.No	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	Income				
	(a) Revenue from Operations	5,711.93	6,728.71	5,720.87	23,213.27
	(b) Other Income	11.17	8.94	14.04	76.31
	Total Income (net) (a+b)	**5,723.10**	**6,737.65**	**5,734.91**	**23,289.58**
2	**Expenses**				
	(a) Cost of Materials Consumed	3,359.45	3,551.08	2,333.37	12,479.22
	(b) Purchase of Stock in trade	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work In Progress and Stock-in-trade	(44.22)	1,165.17	1,624.53	3,208.35
	(d) Employee Benefits Expenses	882.37	817.76	931.25	3,346.17
	(e) Finance costs (net)	367.53	308.24	404.45	1,620.82
	(f) Depreciation and amortization expenses	399.02	456.29	438.09	1,784.34
	(g) Other Expenses	1,425.04	1,730.48	1,296.02	5,649.42
	Total Expenses (a to g)	**6,389.19**	**8,029.02**	**7,027.71**	**28,088.32**
3	**Profit / (Loss) and other income, finance costs but before exceptional items (1-2)**	**(666.09)**	**(1,291.37)**	**(1,292.80)**	**(4,798.74)**
4	Exceptional items	-	-	-	-
5	**Profit/(Loss) from ordinary activities before tax (3-4)**	**(666.09)**	**(1,291.37)**	**(1,292.80)**	**(4,798.74)**
	(a) Current Tax	-	0.07	-	28.88
	(b) Deferred Tax	89.27	14.60	80.00	(446.20)
6	**Tax Expenses**	**89.27**	**14.67**	**80.00**	**(417.32)**
7	**Net Profit(+)/Loss(-) from ordinary activities after tax (5-6)**	**(755.36)**	**(1,306.04)**	**(1,372.80)**	**(4,381.42)**
8	Extraordinary Items	-	-	-	-
9	**Net Profit(+)/Loss (-) for the period(7-8)**	**(755.36)**	**(1,306.04)**	**(1,372.80)**	**(4,381.42)**
10	Share of Profit / (Loss) of associates				
11	Minority Interest				
12	**Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (9-10-11)**	**(755.36)**	**(1,306.04)**	**(1,372.80)**	**(4,381.42)**
13	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	(14.16)	(19.24)	(11.42)	(45.24)
14	**Total Comprehensive Income (12+13)**	**(769.52)**	**(1,325.28)**	**(1,384.22)**	**(4,426.66)**
15	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82
16	Reserve excluding Revaluation Reveres as per balance sheet of previous accounting year	-	-	-	8,749.38
17	**Earnings Per Share (EPS) (of Rs 10/-each not annualised):**				
	(a) Basic	(4.77)	(8.25)	(8.67)	(27.68)
	(b) Diluted	(4.77)	(8.25)	(8.67)	(27.68)

V. S. SOMANI & CO.
M. No. 102664
FRN: 117589
CHARTERED ACCOUNTANTS

MANGALAM DRUGS & ORGANICS LTD.
MUMBAI

MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413
Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

MANGALAM

Notes :

1 The unaudited standalone financial results for the quarter ended June 30, 2026 have been prepared in accordance with Indian Accounting Standard (Ind AS) as prescribed under section 133 of the Companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.

2 The figures for the last quarter are the balancing figures between audited figures in respect of full financial year upto March 31, 2026 and the unaudited published year-to-date figures upto December 31, 2025 being the date of the end of the third quarter of the financial year respectively which were subject to limited review.

3 The unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and thereafter, approved and taken on record by the Board of Directors of the Company (Mangalam Drugs and Organics Limited) at their meeting held on August 12, 2026.

4 The Company's business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".

5 The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Mangalam Drugs and Organics Limited ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to hearing by Hon'ble National Company Law Tribunal.

6 Other Expenses

Rs in Lakhs

Particulars	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited	Unaudited	Audited
Power and Fuel	568.58	440.05	446.30	1,828.81
Pollution Control	149.84	217.46	168.30	660.56

7 The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods classification.

For and on behalf of Board of Directors
For Mangalam Drugs and Organics Limited

Shri Govardhan M.Dhoot
(Chairman and Managing Director)
DIN:01240086

Place:Mumbai
Date: 12th August, 2026

MANGALAM DRUGS & ORGANICS LTD. MUMBAI

V. S. SOMANI & CO. M. No. 102564 FRN 117589 CHARTERED ACCOUNTANTS

V. S. SOMANI & CO.
CHARTERED ACCOUNTANTS

UNIT NO.127, 1ST FLOOR,
PRABHADEVI UNIQUE INDUSTRIAL
PREMISES CO-OP SOCIETY LTD.,
TWIN TOWER LANE,
OFF. VEER SAVARKAR MARG,
PRABHADEVI, MUMBAI 400 025.
PHONE NO: 022 66624558
EMAIL ID: vidyadhar@cavssomani.com

Limited Review Report on Unaudited Consolidated Financial Results of Mangalam Drugs and Organics Limited for the Quarter ended on 30th June, 2026 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021 as amended.

To the Board of Directors,
Mangalam Drugs and Organics Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results ("the Statement") of **Mangalam Drugs and Organics Limited** (hereinafter referred to as "the Parent"), its subsidiary (the Parent and its subsidiary together referred to as "the Group") and its share of the net Loss after tax and total comprehensive income of its subsidiary for the quarter ended 30th June 2026, being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, as amended.

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the requirement of recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

5. The statement includes the results of the Mangalam Laboratories Private Limited a subsidiary, which is not a material subsidiary.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement

Other Matters

7. We did not review the interim financial results of a subsidiary included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs.11.05 Lakhs total net loss after tax and total comprehensive income (before consolidation adjustments) of Rs. 8.52 Lakhs for the quarter ended 30th June 2026 and as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

For V.S. SOMANI & Co.,
Chartered Accountants
Firm Registration No. 117589W

V.Somani

C.A. Vidyadhar Somani
Proprietor
MembershipNo.102664
UDIN No.26102664NEQ6DG7123

Place: Mumbai
Date: August 12th,2026

MANGALAM DRUGS AND ORGANICS LIMITED

CIN - L24230MH1972PLC116413

Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400 001.

Statement of Consolidated Unaudited Financial Results for the Quarter Ended June 30, 2026

(Rs. In Lakhs)

Sr.No	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	**Income**				
	(a) Revenue from Operations	5,711.93	6,728.71	5,720.87	23,213.27
	(b) Other Income	11.17	8.94	14.04	76.31
	Total Income (net) (a+b)	**5,723.10**	**6,737.65**	**5,734.91**	**23,289.58**
2	**Expenses**				
	(a) Cost of Materials Consumed	3,359.45	3,551.08	2,333.37	12,479.22
	(b) Purchase of Stock in trade	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work In Progress and Stock-in-trade	(44.22)	1,165.17	1,624.53	3,208.35
	(d) Employee Benefits Expenses	891.01	848.74	938.10	3,378.75
	(e) Finance costs (net)	367.53	308.25	404.46	1,620.84
	(f) Depreciation and amortization expenses	408.51	465.78	447.57	1,822.31
	(g) Other Expenses	1,415.43	1,725.77	1,286.71	5,637.25
	Total Expenses (a to g)	**6,397.71**	**8,064.79**	**7,034.74**	**28,146.72**
3	**Profit / (Loss) and other income, finance costs but before exceptional items (1-2)**	**(674.61)**	**(1,327.14)**	**(1,299.83)**	**(4,857.14)**
4	Exceptional items	-	-	-	-
5	**Profit/(Loss) from ordinary activities before tax (3-4)**	**(674.61)**	**(1,327.14)**	**(1,299.83)**	**(4,857.14)**
	(a) Current Tax	-	0.26	-	29.07
	(b) Deferred Tax	89.27	14.60	80.00	(446.20)
6	**Tax Expenses**	**89.27**	**14.86**	**80.00**	**(417.13)**
7	**Net Profit(+)/Loss(-) from ordinary activities after tax (5-6)**	**(763.88)**	**(1,342.00)**	**(1,379.83)**	**(4,440.00)**
8	Extraordinary Items	-	-	-	-
9	**Net Profit(+)/Loss (-) for the period(7-8)**	**(763.88)**	**(1,342.00)**	**(1,379.83)**	**(4,440.00)**
10	Share of Profit / (Loss) of associates				
11	Minority Interest				
12	**Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (9-10-11)**	**(763.88)**	**(1,342.00)**	**(1,379.83)**	**(4,440.00)**
13	Other Comprehensive income not reclassified into Profit and loss account (Net of Taxes)	(14.16)	(19.24)	(11.42)	(45.24)
14	**Total Comprehensive Income (12+13)**	**(778.04)**	**(1,361.24)**	**(1,391.25)**	**(4,485.24)**
15	Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82
16	Reserve excluding Revaluation Reveres as per balance sheet of previous accounting year	-	-	-	8,723.08
17	**Earnings Per Share (EPS) (of Rs 10/-each not annualised):**				
	(a) Basic	(4.83)	(8.48)	(8.72)	(28.05)
	(b) Diluted	(4.83)	(8.48)	(8.72)	(28.05)

V. S. SOMANI & CO. M. No. 102664 FRN 117589 CHARTERED ACCOUNTANTS

MANGALAM DRUGS & ORGANICS LTD. MUMBAI

MANGALAM DRUGS AND ORGANICS LIMITED
CIN - L24230MH1972PLC116413
Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai - 400001.

MANGALAM

Notes :

1 The unaudited consolidated financial results of Mangalam Drugs and Organics Limited ("the Company or the Parent Company and its subsidiary referred as the "Group") for the quarter ended June 30, 2026 have been prepared in accordance with Indian Accounting Standard (Ind AS) as prescribed under section 133 of the Companies Act, 2013, read together with Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.

2 The figures for the last quarter are the balancing figures between audited figures in respect of full financial year upto March 31, 2026 and the unaudited published year-to-date figures upto December 31, 2025 being the date of the end of the third quarter of the financial year respectively which were subject to limited review.

3 The above unaudited consolidated financial results of the Group for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and thereafter, approved by the Board of Directors at their meeting held on August 12, 2026.

4 The Group has business activity falls within a single reportable Business Segment Viz. "Manufacturing of Bulk Drugs".

5 The Consolidated results includes results of Mangalam Laboratories Private Limited (MLPL), Wholly-owned subsidiary of the Company for the purpose of Consolidated results and it is not a material subsidiary of the Company.

6 The Board of Directors of the Company at its meeting held on March 15, 2024 had considered and approved the scheme of Merger by Absorption of its Wholly-owned subsidiary ("First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("Second Transferor Company") with Parent Company ("Transferee Company") and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013. The Scheme is subject to hearing by Hon'ble National Company Law Tribunal.

7 Other Expenses

Rs in Lakhs

Particulars	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited	Unaudited	Audited
Power and Fuel Expenses	568.73	440.18	446.44	1,829.35
Pollution Control Expenses	149.84	217.46	168.30	660.56

8 The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods classification.

For and on behalf of Board of Directors
For Mangalam Drugs and Organics Limited

Place:Mumbai
Date: 12th August, 2026

Shri Govardhan M.Dhoot
(Chairman and Managing Director)
DIN:01240086

MANGALAM DRUGS & ORGANICS LTD. MUMBAI

V. S. SOMANI & CO. M. No. 102664 FRN: 117589 CHARTERED ACCOUNTANTS

Annexure II

Details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No.	Particulars	Details
1.	Name	M/s L.N. Joshi & Co., Practicing Company Secretaries
2.	Reason for Change	Appointment of M/s L.N. Joshi & Co., Practicing Company Secretaries as Secretarial Auditors of the Company in line with SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024
3.	Date of Appointment / Term of Appointment	The Board approved appointment in its meeting held on August 12, 2026 for a period of five consecutive years commencing from F.Y.2026- 27 till F.Y. 2030-31 subject to approval of shareholders in ensuing 53rd Annual General Meeting.
4.	Brief Profile (In case of appointment) & Experience	M/s L.N. Joshi & Co., Practicing Company Secretaries has over 25 years of experience in corporate laws, securities laws, secretarial audits, corporate restructuring, due diligence, regulatory compliances and advisory services. The firm has a dedicated team for carrying out Secretarial Audit. The firm has served diversified industries.
5.	Disclosure of Relationship between Directors	Not Applicable

Annexure III

Details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No.	Particulars	Details
1.	Name	M/s S.N. Nanda & Co., Chartered Accountants
2.	Reason for Change	Appointment of M/s S.N. Nanda & Co., Chartered Accountants (FRN:000685N) as Statutory Auditors of the Company in line with SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024
3.	Date of Appointment / Term of Appointment	The Board approved appointment in its meeting held on August 12, 2026 for a period of five consecutive years commencing from F.Y.2026- 27 till F.Y. 2030-31 subject to approval of shareholders in ensuing 53rd Annual General Meeting.
4.	Brief Profile (In case of appointment) & Experience	M/s S.N. Nanda & Co., Chartered Accountants (FRN:000685N) has over 60 years of experience in conducting the audit of Public Sector Undertakings, Banks, Companies & other organizations. M/s S.N. Nanda & Co., has been providing its expert services to its clients in India Globally in all the major sectors of the economy to their satisfaction.
5.	Disclosure of Relationship between Directors	Not Applicable